1. Li, Zhipeng, Zhou, Huaxin, Zhai, Xiangyu, Wang, Wei, Jin, Bin. 2023. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function. In Cell death & disease, 14, 733. doi:10.1038/s41419-023-06264-3. https://pubmed.ncbi.nlm.nih.gov/37949877/
2. Tang, Bufu, Zhu, Jinyu, Shi, Yueli, Chen, Minjiang, Ji, Jiansong. 2024. Tumor cell-intrinsic MELK enhanced CCL2-dependent immunosuppression to exacerbate hepatocarcinogenesis and confer resistance of HCC to radiotherapy. In Molecular cancer, 23, 137. doi:10.1186/s12943-024-02049-0. https://pubmed.ncbi.nlm.nih.gov/38970074/
3. Zhu, Xinhua, Zhang, Erjia, Qin, Li. 2024. The high expression of TOP2A and MELK induces the occurrence of psoriasis. In Aging, 16, 3185-3199. doi:10.18632/aging.205519. https://pubmed.ncbi.nlm.nih.gov/38382096/
4. Yang, Haiyan, Zhou, Huandi, Wang, Guohui, Zhang, Yufeng, Xue, Xiaoying. 2022. MELK is a prognostic biomarker and correlated with immune infiltration in glioma. In Frontiers in neurology, 13, 977180. doi:10.3389/fneur.2022.977180. https://pubmed.ncbi.nlm.nih.gov/36353126/
5. Xu, Qinyang, Ge, Qiulin, Zhou, Yang, Zhang, Zhigang, Teng, Yincheng. 2020. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway. In EBioMedicine, 51, 102609. doi:10.1016/j.ebiom.2019.102609. https://pubmed.ncbi.nlm.nih.gov/31915116/
6. Hardeman, Ashley A, Han, Yoo Jane, Grushko, Tatyana A, Zheng, Yonglan, Olopade, Olufunmilayo I. 2022. Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. In PloS one, 17, e0268693. doi:10.1371/journal.pone.0268693. https://pubmed.ncbi.nlm.nih.gov/35749404/
智鼠故事 
